The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.
The effect of saralasin in lowering blood pressure and plasma aldosterone concentration in normal subjects, both sodium-replete and sodium-deplete, and in patients with various forms of hypertension, is closely related to the basal plasma angiotensin II concentration. These findings confirm and extend earlier studies of angiotensin II/arterial pressure and angiotensin II/aldosterone dose-response curves. They also emphasize the importance of the renin-angiotensin system in the control of aldosterone in sodium depletion and in renal hypertension.
D000450:Aldosterone / Q000097:blood*; D000804:Angiotensin II / Q000031:analogs & derivatives* / Q000097:blood*; D001794:Blood Pressure / Q000187:drug effects*; D004032:Diet; D006801:Humans; D006929:Hyperaldosteronism / Q000097:blood / Q000150:complications / Q000503:physiopathology; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000503:physiopathology; D008297:Male; D012078:Renal Artery Obstruction / Q000097:blood / Q000150:complications / Q000503:physiopathology; D012083:Renin / Q000097:blood; D012504:Saralasin / Q000494:pharmacology*; D012964:Sodium / Q000502:physiology; D013997:Time Factors
D000804:Angiotensin II; D000450:Aldosterone; D012964:Sodium; D012083:Renin; D012504:Saralasin